September 29, 2025 - Regulatory Proposal for a resolution on authorization for the Board of Directors to resolve on acquisition and transfer of own shares
July 15, 2025 - Regulatory Correction: SynAct to receive SEK 17.7 million after conversion of warrants
June 4, 2025 - Regulatory SynAct Pharma AB carries out a directed share issue of SEK 37 million and extends its financial runway to end of 2026
June 3, 2025 - Regulatory SynAct Pharma takes out a credit facility of SEK 30 million that extends the company’s financial runway to mid-2026, which strongly strengthens partnership opportunities.
February 20, 2025 - Regulatory SynAct’s Nomination Committee proposes Jeppe Ragnar Andersen to the Board
December 17, 2024 - Regulatory SynAct Pharma AB publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm
November 20, 2024 - Regulatory SynAct Pharma intends to carry out directed issues totalling approximately 45 MSEK and a fully guaranteed rights issue totalling approximately 20 MSEK
April 23, 2024 - Regulatory Changes in SynAct Pharma’s Nomination Committee ahead of the 2024 Annual General Meeting
March 27, 2024 - Regulatory SynAct Pharma AB has successfully completed the bookbuilding procedure – directed issues provide the company with a total of up to 49.2 MSEK.
March 26, 2024 - Regulatory SynAct Pharma AB announces intention to carry out directed share issues in total of approximately 48 MSEK
March 25, 2024 - Regulatory SynAct Pharma AB (publ) (“SynAct”) brings forward the publication of the annual report.
March 10, 2024 - Regulatory SynAct Pharma announces outcomes of the independent audit of the 4-week RESOLVE P2a clinical trial in Rheumatoid Arthritis
February 23, 2024 - Regulatory SynAct Pharma AB (publ) (“SynAct”) today publishes the fourth quarter and annual results of 2023.
January 28, 2024 - Regulatory The Board of Directors of SynAct Pharma AB has received a request to convene an EGM
November 1, 2023 - Regulatory SynAct Pharma announces evaluation of the 4-week RESOLVE P2a clinical trial in moderate to severely active rheumatoid arthritis patients with an incomplete response to methotrexate
October 12, 2023 - Regulatory SynAct Pharma AB publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm
October 11, 2023 - Regulatory SynAct Pharma AB carries out a directed issue of shares and warrants raising initial gross proceeds of SEK 60.5 million
September 12, 2023 - Regulatory SynAct Pharma announces additional data from the EXPAND P2b clinical trial and identifies population with responsiveness to resomelagon
September 4, 2023 - Regulatory SynAct Pharma announces top line data from the 12-week EXPAND P2b clinical trial in severely active newly diagnosed rheumatoid arthritis patients
May 25, 2023 - Regulatory Bulletin from the annual general meeting in SynAct Pharma AB on May 25, 2023
April 24, 2023 - Regulatory SynAct Pharma completes patient recruitment for Phase 2b EXPAND study of AP1189 in early severe Rheumatoid Arthritis
April 3, 2023 - Regulatory The Nomination Committee of SynAct Pharma proposes Uli Hacksell as new Chairman and Thomas von Koch as new Board member
February 1, 2023 - Regulatory Patrik Renblad is leaving SynAct Pharma and the search for a new CFO has been initiated
December 12, 2022 - Regulatory SynAct Pharma to make strategic acquisition of Swiss biotech company TXP Pharma
December 12, 2022 - Regulatory SynAct Pharma carries out a directed share issue of SEK 80 million in connection with the acquisition of TXP Pharma
May 20, 2022 - Regulatory Bulletin from the annual general meeting in SynAct Pharma AB on May 20, 2022
May 12, 2022 - Regulatory Last day of trading in paid subscribed shares (Sw. betalda tecknade aktier) in SynAct Pharma AB
March 28, 2022 - Regulatory Bulletin from the extraordinary general meeting on March 28, 2022, in SynAct Pharma AB
March 28, 2022 - Regulatory SynAct resolves on a fully guaranteed rights issue of approximately SEK 150 million
March 9, 2022 - Regulatory The Nomination Committee proposes Kerstin Hasselgren as a new board member of SynAct Pharma AB
November 30, 2021 - Regulatory SynAct Pharma’s AP1189 meets primary endpoint and demonstrates favorable safety profile in Rheumatoid Arthritis patients with active joint disease in the Phase 2a BEGIN study
September 24, 2021 - Regulatory SynAct Pharma completes patient recruitment to the Phase 2a BEGIN study of AP1189 in early severe Rheumatoid Arthritis
August 27, 2021 - Regulatory SynAct Pharma: Interim Report January-June 2021 August 27, 2021 (Q2 2021 Report included)
August 27, 2021 - Regulatory SynAct Pharma Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis
August 25, 2021 - Regulatory SynAct strengthens IP portfolio – Grant of key European patent covering AP1189
August 20, 2021 - Regulatory SynAct Pharma to present new data on AP1189 for the treatment of rheumatoid arthritis at ACR Convergence 2021
July 7, 2021 - Regulatory SynAct Pharma Appoints Anders Dyhr Toft, MD, Ph.D., as Chief Medical Officer
July 7, 2021 - Regulatory SynAct Pharma AB Announces Additional Data from the Phase 2a Trial of AP1189 in Covid-19 Infected Patients and Reminds of Management Call to Discuss Results
July 2, 2021 - Regulatory SynAct Pharma Hosts Conference Call on Positive Data from a Phase 2a Trial of AP1189 in Covid-19 Infected Patients
June 30, 2021 - Regulatory SynAct Pharma AB Announces Positive Data from a Phase 2a Trial of AP1189 in Covid-19 Infected Patients
June 23, 2021 - Regulatory SynAct Pharma Files Patent Applications Related to AP1189 Derived APIs and Oral Formulations
June 1, 2021 - Regulatory SynAct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients
May 21, 2021 - Regulatory Bulletin from the annual general meeting in SynAct Pharma AB on 21 May 2021
May 14, 2021 - Regulatory SynAct Pharma AB: SynAct Pharma initiates collaboration on pharmacogenetic aspects of AP1189 compound in Rheumatoid arthritis with Barts and London School of Medicine, Queen Mary University of London.
May 12, 2021 - Regulatory SynAct Pharma partners with Örebro University to study cardiovascular disease
April 30, 2021 - Regulatory SynAct Pharma to participate at Kempen’s virtual Life Sciences Conference
April 13, 2021 - Regulatory SynAct strengthens IP portfolio – Receives “Intention to Grant” from the European Patent Office for a key patent covering AP1189 English version
March 18, 2021 - Regulatory SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version
March 1, 2021 - Regulatory SynAct Pharma’s CFO and board member sell shares to cover taxes on holdings
February 11, 2021 - Regulatory SynAct Pharma Names James Knight as Chief Business Officer – Already published in Swedish today
February 5, 2021 - Regulatory SynAct carries out a directed share issue and raises proceeds of SEK 80 million
February 4, 2021 - Regulatory SynAct explores the conditions for carrying out a directed share issue – English version – Published today 17.31 CET
February 4, 2021 - Regulatory SynAct Pharma prepares move to Nasdaq Stockholm – English version – Published today at 17.31 CET
January 11, 2021 - Regulatory Published in English – already published 11:18 CET today Disclosure notice in SynAct Pharma AB
November 9, 2020 - Regulatory SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis
November 6, 2020 - Regulatory Bulletin from the extraordinary shareholders’ meeting in SynAct Pharma AB
October 20, 2020 - Regulatory Shareholders of SynAct Pharma proposes Uli Hacksell as new board member
October 12, 2020 - Regulatory English version of PR published 20201012 at 07.33AM SynAct Pharma completes part 1 of clinical phase II study with AP1189 in Rheumatoid Arthritis
September 23, 2020 - Regulatory Swedish version of press release published earlier today. SynAct Pharma initierar fas II-studie med AP1189 för behandling av ARDS i COVID-19-patienter
September 23, 2020 - Regulatory SynAct Pharma Initiates Phase II Study with AP1189 for the Treatment of ARDS in COVID-19 Patients
September 3, 2020 - Regulatory SynAct Pharma informs that the recruitment to part 1 in the Clinical Phase II study with AP1189 in Rheumatoid Arthritis is completed
September 1, 2020 - Regulatory SynAct Pharma Informs about Termination of Coverage Agreement with Redeye
August 28, 2020 - Regulatory SynAct Pharma Initiates RESOVIR: Scientific and clinical Collaboration to Explore AP1189 in Viral Infections
July 27, 2020 - Regulatory Synact Pharma announces outcome in the exercise of warrants, will receive approximately MSEK 32.4
July 15, 2020 - Regulatory SynAct Pharma AB: Update on SynAct Pharma´s Clinical Phase II study with AP1189 in Rheumatoid Arthritis
June 30, 2020 - Regulatory SynAct Pharma announces that the exercise period for warrants of the TO 2 series will start on July 1, 2020
June 29, 2020 - Regulatory SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome
June 25, 2020 - Regulatory SynAct Pharma’s Board of Directors and management sign subscription commitment for warrant exercise of series TO 2
June 2, 2020 - Regulatory SynAct Pharma´s clinical trial application for AP1189 in Nephrotic Syndrome approved by the Danish Medical Agency
May 25, 2020 - Regulatory SynAct Pharma files patent application for combination of AP1189 and Methotrexate for treatment of RA and other arthritic diseases
May 5, 2020 - Regulatory SynAct presents initial data from the first part of the Phase II study within RA and gives an update on its progression
March 31, 2020 - Regulatory SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome
March 31, 2020 - Regulatory Translation – UK version of Swedish press release – published 08.00 AM. today – SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19
October 21, 2019 - Regulatory SynAct conducts private placement and fully guaranteed rights issue with the aim of increasing the commercial value of AP1189
March 29, 2019 - Regulatory SynAct applies for start of phase IIa clinical study in patients with active arthritis
February 11, 2019 - Regulatory SynAct reported positive phase I results for candidate drug AP1189 and prepared funding for broadened phase II programmes
December 21, 2018 - Regulatory Dosing with candidate drug AP1189 in multiple-dose part of the Phase I study completed
December 10, 2018 - Regulatory SynAct’s candidate drug AP1189 exhibits continued favourable safety and plasma profiles in the multiple-dose part of the Phase I study
October 22, 2018 - Regulatory SynAct Pharma announced that AP1189 exhibits a favourable plasma profile in the Phase I study’s initial multiple-dose part
September 13, 2018 - Regulatory SynAct Pharma announced the start of the multiple-dose part of the Phase I study with AP1189
August 20, 2018 - Regulatory SynAct Pharma announced positive data from preclinical study in nephrotic syndrome with candidate drug AP1189
July 23, 2018 - Regulatory SynAct Pharma obtains regulatory approval for the implementation of the multiple-dose part in Phase I study with candidate drug AP1189
June 12, 2018 - Regulatory SynAct Pharma adapts the continued clinical development programme for AP1189 based on new results from the Phase I study
April 10, 2018 - Regulatory Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)
March 23, 2018 - Regulatory SynAct Pharma proposes a rights issue of SEK 22.4 million in order to increase the market potential for AP1189.
October 3, 2017 - Regulatory The first part of the clinical Phase I study with SynAct Pharma’s drug candidate AP1189 successfully completed
May 10, 2017 - Regulatory SynAct Pharma AB receives approval to start Clinical Phase I study with AP1189 – a new potential treatment for psoriatic arthritis
April 27, 2017 - Regulatory Utilisation of subscription options registered with Swedish Companies Registration Office
April 25, 2017 - Regulatory SynAct Pharma AB provides an update on the clinical development plan for AP1189
March 31, 2017 - Regulatory SynAct Pharma AB will raise 1,007,539.20 SEK through the utilisation of series TO 1 subscription options
March 9, 2017 - Regulatory SynAct Pharma AB retains subscription rights for series TO 1subscription option
March 9, 2017 - Regulatory The utilisation period of SynAct Pharma AB’s series TO 1 subscription options starts today
February 22, 2017 - Regulatory SynAct Pharma AB has received approval from the Ethics Committee and continues its dialogue with the French Medicines Agency
